Nautilus Biotechnology (NAUT) Total Current Liabilities (2020 - 2026)

Nautilus Biotechnology has disclosed Total Current Liabilities across 7 years of filings, most recently posting $8.3 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $8.3 million, up 2.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.3 million (up 2.29% YoY), and the FY2025 annual result was $8.0 million, up 4.19% from the prior year.
• Total Current Liabilities came in at $8.3 million for Q1 2026 at Nautilus Biotechnology, up from $8.0 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $9.2 million in Q1 2024 to a low of $6.1 million in Q2 2022.
• The 5-year median for Total Current Liabilities is $8.1 million (2025), against an average of $8.0 million.
• Across the five-year window, Total Current Liabilities surged 256.02% in 2022 and slipped 16.33% in 2024, its largest moves.
• Nautilus Biotechnology's Total Current Liabilities stood at $6.8 million in 2022, then soared by 34.32% to $9.1 million in 2023, then decreased by 16.33% to $7.6 million in 2024, then grew by 4.19% to $8.0 million in 2025, then climbed by 4.92% to $8.3 million in 2026.
• The last three Total Current Liabilities figures came in at $8.3 million (Q1 2026), $8.0 million (Q4 2025), and $9.0 million (Q3 2025), per Business Quant data.